Cha-Mer Wei

Title: Cha-Mer Wei: Innovator in Mutagenesis and Urokinase Research

Introduction

Cha-Mer Wei is a notable inventor based in Worcester, MA (US). He has made significant contributions to the fields of mutagenesis and protein engineering, holding a total of 3 patents. His innovative work has implications for both medical research and therapeutic applications.

Latest Patents

Wei's latest patents include a "Rapid screening mutagenesis and teratogenesis assay." This invention provides a rapid, sensitive, and quantitative method for screening compounds for mutagenic or teratogenic activity using transgenic animal cells and adult or embryonic transgenic animals. The assay system is designed to detect changes in gene expression through a target gene and a reporter gene, allowing for efficient identification of harmful compounds.

Another significant patent is related to "Inhibitor-resistant urokinase." This invention involves producing mutants of human urokinase with an altered amino acid sequence that enhances resistance to plasminogen activator inhibitors. The gene encoding this inhibitor-resistant preprourokinase is synthesized using computer-designed nucleotide sequences, enabling high-level expression in cultured mouse cells. This innovation has potential applications in therapeutic protein production.

Career Highlights

Cha-Mer Wei has worked with prominent companies such as Genzyme Corporation and TSI, Inc. His experience in these organizations has contributed to his expertise in biotechnological innovations and research.

Collaborations

Wei has collaborated with notable colleagues, including Vermuri B Reddy and Nancy Hsiung, who have contributed to his research endeavors.

Conclusion

Cha-Mer Wei's contributions to mutagenesis and urokinase research highlight his role as an influential inventor in the biotechnology field. His innovative patents continue to pave the way for advancements in medical research and therapeutic applications.